Journal of Clinical & Experimental Pharmacology

Mashako MR

Publications

• Research Article
  Artesunate versus Quinine in the Treatment of Severe Plasmodium falciparum Malaria at North Eastern of Democratic Republic of Congo: Parasites and Fever Clearance
  Author(s): Ngbonda ND, Alworonga JO, Mashako MR, Batoko BL, Falay D, Tebandite EK, Muyobela V, Apio N, Nkinamubanzi M and Mande GNgbonda ND, Alworonga JO, Mashako MR, Batoko BL, Falay D, Tebandite EK, Muyobela V, Apio N, Nkinamubanzi M and Mande G
  
  Severe malaria is one of the leading causes of death in sub-Saharan African countries and Artesunate is the firstline choice recommended treatment by the World Health Organization. The objective of this study was to identify biological and clinical advantages of Artesunate compared to Quinine in the treatment of severe malaria in children. This study was a randomized and analytical study focused on children admitted to Pediatric Hospital Center Village of Kisangani with severe falciparum malaria, from January 1, 2015 to December 31, 2017. We assigned individuals children intravenous Artesunate 2.4 mg/kg given as a bolus (n=34) at 0, 12, 24 hours and then daily or Quinine 20 mg/kg infused in 5 or 10% Dextrose over 4 hours than 10 mg/kg infused every 8 hours (n=83). During our study period, a total of 117 children were included in the study. 34 were treated with Artesunate while 83 were.. View More»
  DOI: 10.4172/2161-1459.1000253

  Abstract PDF